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and 18 s (16; 22) versus 16 s (15; 20), p < 0.01], whereas CTO 
remained unchanged. Arterial oxygen saturation, NYHA 
class, 6MWD and HRQoL had also improved. Baseline CTO 
was the strongest predictor of cognitive function, even in 
multivariate analysis including age, 6MWD and HRQoL. Im-
provements in cognitive function were not associated with 
changes in CTO.  Conclusions: In patients with PH, 3 months 
of disease-targeted medication resulted in better cognitive 
function. Although CTO was the strongest predictor of cog-
nitive function at baseline, it did not change during target 
therapy. The results of this pilot study should be confirmed 
in an adequately powered controlled trial. 
 © 2015 S. Karger AG, Basel 
 Introduction 
 Precapillary pulmonary hypertension (PH) is defined 
by a mean pulmonary artery pressure of  ≥ 25 mm Hg, 
along with a pulmonary artery wedge pressure of  ≤ 15 
mm Hg  [1] .
 PH leads to fatigue and reduced exercise capacity and 
may be associated with cognitive deficits  [2] . Only one 
study has so far investigated cognitive function in pa-
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 Abstract 
 Background: Patients with pulmonary hypertension (PH) 
may suffer from cognitive deficits that potentially relate to 
reduced oxygen delivery and cerebral tissue oxygenation 
(CTO).  Objective: To evaluate the hypothesis that cognitive 
function improves with therapy, along with improved CTO. 
 Methods: Twenty incident patients with arterial or chronic 
thromboembolic PH had CTO monitoring by near-infrared 
spectroscopy during diagnostic right heart catheterization. 
Cognitive tests [Trail Making Tests (TMTs), Victoria Stroop 
tests and the Five-Point Test (5PT)], the 6-min walk distance 
(6MWD) test, New York Heart Association (NYHA) class and 
health-related quality of life (HRQoL) were assessed and re-
peated after 3 months of disease-targeted medication.  Re-
sults: At baseline, 45% of PH patients had cognitive deficits. 
At 3 months, the patients had improved on the TMT A and 
the Stroop 2 test [37 s (27; 55) versus 30 s (24; 42), p < 0.05, 
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tients with pulmonary arterial hypertension (PAH)  [2] . 
Cognitive deficits were found in more than half of PAH 
patients and mainly presented as worsening in verbal 
learning, delayed verbal memory, reduced executive 
function and failed fine motor scores. A decline in cogni-
tive function might also be associated with reduced 
health-related quality of life (HRQoL), which itself is 
known to be associated with disease progression  [3–6] .
 PH leads to hypoxemia, mainly due to a reduced car-
diac output and mixed venous oxygen saturation (SmvO 2 ), 
especially during exercise  [7] , but little is known about 
cerebral tissue oxygenation (CTO). In healthy and dis-
eased adults, lower CTO has been shown to be correlated 
with impaired cognitive function  [8–11] . The brain is a 
key factor for exercise limitation in healthy people, and 
this might especially be true for patients with cardiorespi-
ratory diseases, where a central limiting mechanism pro-
tects organs from severe exercise-induced hypoxia  [12–
15] . In line with this, we have recently shown that PH 
patients have reduced CTO during exercise and that CTO 
can be improved by acute pulmonary vasodilation with 
nitric oxide or supplemental oxygen  [13] . However, it is 
not known whether these favorable effects are maintained 
after long-term pulmonary vasodilation with PH-target-
ed therapies.
 Therefore, our aim was to study cognitive function in 
newly diagnosed patients with PAH or inoperable chron-
ic thromboembolic PH at baseline and after 3 months of 
disease-targeted medical treatment. A further aim was to 
assess whether cognitive function might be linked to CTO 
and to study its relationship with functional and exercise 
capacity, arterial oxygenation and HRQoL  [1, 16] .
 Methods 
 Patients 
 This is a single-center study performed at the University Hos-
pital of Zurich between June 2011 and October 2014. Patients with 
PAH or chronic thromboembolic PH who were scheduled for di-
agnostic right heart catheterization (RHC) and had planned fol-
low-up (FU) visits were included upon written informed consent. 
Part of the patients had participated in a previous study that deter-
mined the effects of acute vasodilator therapy, supplemental oxy-
gen and exercise on CTO and blood flow during RHC  [13] . The 
study was approved by the Zurich Cantonal Ethics Review Board 
and registered (Clinicaltrials.gov, NCT01463514).
 Study Assessments 
 Demographics, medical history, New York Heart Association 
(NYHA) functional class and HRQoL – Minnesota Living with 
Heart Failure Questionnaire (MLHFQ) and Cambridge Pulmo-
nary Hypertension Outcome Review (CAMPHOR)  [3, 17] – were 
assessed. The 6-min walk distance (6MWD) test was performed 
according to guidelines  [18] . Heart rate, systolic and diastolic 
blood pressure as well as arterial oxygen saturation (SaO 2 ) were 
assessed before and at the end of the 6MWD test.
 A Mini Mental State Examination (MMSE) and a clock test 
were conducted at baseline, and the patients’ educational level was 
assessed. Patients underwent cognitive testing at baseline and at 
FU after 3 months, including the Trail Making Tests (TMTs) A and 
B that are validated tools for measuring processing speed (part A) 
and executive function (part B)  [19, 20] . The Stroop tests are con-
sidered measures of cognitive flexibility and control as well as of 
executive functioning  [21] . The Five-Point Test (5PT)  [22] is used 
to examine figural fluency. All three are widely accepted instru-
ments for cognitive testing. On TMT A and B, we used normative 
data of a Swiss sample, stratified by age and gender and corrected 
for education level  [19, 20] . For the Stroop test and the 5PT, we 
used age- and education-stratified normative data that were col-
lected in North America and Germany, respectively  [21, 22] . An 
abnormal result in the cognitive tests was defined as a score deviat-
ing by more than 2 standard deviations (SD) from the mean nor-
mative data.
 All patients had standard RHC, including assessments of the 
heart rate, mean arterial and pulmonary artery pressure, pulmo-
nary artery wedge pressure and right atrial pressure. The cardiac 
output was continuously measured by thermodilution (Vigilance 
II, Edwards Lifesciences, Irvine, Calif., USA). Systemic and pulmo-
nary vascular resistance and the cardiac index (cardiac output di-
vided by body surface area) were calculated.
 Blood Analysis and Oximetry 
 During catheterization, arterial and mixed venous blood gases 
were immediately analyzed (oxygen saturation at rest, arterial pH, 
arterial partial pressure of oxygen and carbon dioxide), and the 
arterial blood gas analysis was repeated after 3 months of FU (ABL 
90 FLEX blood gas analyzer, Radiometer GmbH). NT-pro-BNP 
and highly sensitive C-reactive protein were determined in venous 
blood samples in the central hospital laboratory by ELISA at base-
line and after 3 months.
 Cerebral and Muscle Tissue Oxygenation by Near-Infrared 
Spectroscopy 
 CTO and quadriceps muscle tissue oxygenation (QMTO) were 
recorded by near-infrared spectroscopy (NIRS; INVOS, Somanet-
ics Corporation, Troy, Mich., USA) in a supine position after at 
least 10 min of rest and averaged over the following 10 min of rest 
at the day of RHC and after 3 months of FU. Two optic sensors 
(optodes) were placed on the left and right forehead above the 
frontal sinus and bilaterally above the vastus medialis of the quad-
riceps muscles. CTO and QMTO were measured in 6-second in-
tervals. NIRS data from the left and right body sites were analyzed, 
and the signal with the averaged highest value was taken for final 
analysis.
 Statistics 
 SPSS 22 (SPSS Inc., Chicago, Ill., USA) and Excel (Microsoft Of-
fice package) were used for statistical analyses. Data were summa-
rized by medians (quartiles) due to the small sample size and most-
ly non-normal distributions. Changes from baseline to FU were 
evaluated using Wilcoxon’s matched-pair test. Pearson’s correlation 
and stepwise multiple regression were used for uni- and multivariate 
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CTO assessed during
RHC (n = 51)
PH patients with CTO
assessed at FU (n = 28)
Included in FU analysis (n = 20)
- Phosphodiesterase type 5 inhibitor (n = 3)
- Endothelin receptor antagonist (n = 13)
- Calcium channel blocker (n = 3)
- Soluble guanylate cyclase stimulator (n = 3)
- 2 combination therapies
- Technical problems (n = 4)
- No PH (n = 15)
- FU refused (n = 4)
- Therapy refused by patient (n = 3)
- Pretreated with PH-targeted therapy (n = 1)
- Pulmonary endarterectomy (n = 4)
 Fig. 1. Flow diagram of patients scheduled 
for RHC included in the study and ana-
lyzed. 
Participants (females) 20 (13)
Age, years 66 (44; 73)
Body mass index 25 (23; 28)
NYHA Class (II, III, IV) 8 (40), 10 (50), 2 (10)
Education level, years 12.5 (10.5; 15)
MMSE, points 29 (29; 30)
Classification
PAH 15 (75)
Idiopathic 9 (45)
Associated with connective tissue disease 5 (25)
Associated with portal hypertension 1 (5)
Inoperable chronic thromboembolic PH 5 (25)
Treatment started
Endothelin receptor antagonist 13
Phosphodiesterase 5 inhibitor 4
Soluble guanylate cyclase stimulator 3
Calcium channel blocker 1
Combination therapy1 1
Hemodynamics
Heart rate, beats/min 77 (68; 86)
Systolic blood pressure, mm Hg 125 (116; 149)
Diastolic blood pressure, mm Hg 80 (74; 89)
Mean pulmonary arterial pressure, mm Hg 37 (30; 49)
Cardiac index, l/min/m2 3.3 (2.6; 3.7)
Pulmonary vascular resistance, dynes × s × m2 395 (211; 477)
 Values are given as numbers (percentages) or medians (quartiles). Cardiac index = 
Cardiac output/body surface area.
1 Combination therapy: endothelin receptor antagonist/phosphodiesterase 5 inhibitor.
 Table 1.  Baseline characteristics
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
19
8.
14
3.
58
.1
 - 
11
/1
7/
20
15
 1
:3
5:
20
 P
M
 Somaini   et al.
 
Respiration
DOI: 10.1159/000439227
4
analysis. We used 3 different cognitive tests providing a total of 11 
parameters and 2 different HRQoL tests providing 6 parameters. As 
the respective cognitive and HRQoL parameters intercorrelated, the 
parameters were converted into one new component each for cogni-
tion and HRQoL at baseline and FU using dimension reduction. A 
p value <0.05 was taken for statistical significance.
 Results 
 Patients 
 From the 51 subjects who underwent RHC with NIRS 
assessment, 20 patients were newly diagnosed with PH 
and had medical therapy ( fig.  1 ). Characteristics are 
shown in  table  1 . PH-targeted treatment during the 3 
months of FU consisted of endothelin receptor antago-
nists (n = 13), phosphodiesterase 5 inhibitors (n = 4), sol-
uble guanylate cyclase stimulators (n = 3) or calcium 
channel blockers (n = 1). One patient received combina-
tion therapy.
 Baseline Cognitive Testing 
 At baseline, 2 (4%) patients had a pathologic TMT, 5 
(25%) had an abnormal Stroop test (1, 2 or 3) and 9 (45%) 
had an abnormal 5PT ( fig. 2 ).
 Change with Disease-Targeted Therapy 
 After 3 months of FU, in patients with newly intro-
duced disease-targeted medical treatment, 3 patients 
 Table 2. Changes after 3 months
Cognitive tests Baseline FU after 3 months Δ (SD)
5PT, total, n 33 (26; 39) 36 (29; 46)   2 (8)
5PT, invalid, n 3 (1; 9) 4 (1; 8)  – 1.5 (7.5)
5PT, invalid, % 9.7 (1.4; 30.2) 11 (1; 25)  – 2.9 (13.1)
TMT A, time, s 37 (27; 55) 30 (24; 42)  – 3.8 (21)*
TMT B, time, s 92 (56; 135) 76 (57; 136)  – 4.3 (47.7)
Stroop test 1, time, s 17 (13; 21) 15 (12; 18)  – 1.6 (6)
Stroop test 2, time, s 18 (16; 22) 16 (15; 20)  – 2.8 (3.7)**
Stroop test 3, time, s 29 (24; 37) 28 (22; 39)   0.6 (9.7)
Functional, vital and blood parameters
NYHA functional class 3 (2; 3) 2 (2; 3)  – 0.4 (0.7)*
6MWD, m 508 (364; 602) 543 (365; 625)   18 (44)*
Heart rate, bpm 83 (71; 91) 86 (76; 94)   4 (17)
Systolic blood pressure, mm Hg 125 (116; 149) 118 (111; 130)   –10.5 (16.4)*
Diastolic blood pressure, mm Hg 80 (74; 89) 76 (70; 87)  – 3.3 (10.3)
SpO2 peak walk, % 91 (88; 94) 93 (85; 97)   0.1 (5)
Heart rate peak walk, bpm 109 (101; 131) 110 (99; 129)   –1 (15)
NT-proBNP, ng/l 278 (110; 1,920) 159 (77; 1,842)   –339 (1,606)
C-reactive protein, mg/l 2.4 (1.3; 9.0) 2.5 (1.3; 6.6)  – 2.4 (8.8)
Blood and tissue oxygenation
Arterial partial pressure of oxygen, kPa 9.6 (8.1; 10.6) 10.3 (8.8; 11.3)   0.8 (0.8)**
Arterial partial pressure of carbon dioxide, kPa 4.7 (4.4; 5.1) 4.7 (4.3; 5.0)   –0.02 (0.46)
SaO2, measured in hemoglobin, % 94 (90, 95) 95 (93; 96)   1.5 (2.2)*
Cerebral tissue oxygenation, % 66 (61; 70) 65 (58; 69)   0.2 (7.7)
QMTO, % 82 (75; 83) 83 (76, 90)   3.9 (8.2)
QoL
CAMPHOR symptoms, points 8 (4; 14) 5 (3; 11)  – 2.5 (4.5)*
CAMPHOR activity, points 4 (2; 11) 4 (2; 8)   –1 (4.5)
CAMPHOR QoL, points 4 (1; 8.5) 3 (1; 11)  – 0.5 (4.5)
MLHFQ general, points 32 (12; 54) 19 (11; 33)   –10 (21)
MLHFQ physical, points 18 (9; 23) 11 (5; 14)  – 5.5 (9.5)*
MLHFQ emotional, points 7 (2; 13) 5 (2; 10)   –2 (6.5)
Values are given as medians (quartiles) and differences in means (SD). * p < 0.05; ** p < 0.01.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
19
8.
14
3.
58
.1
 - 
11
/1
7/
20
15
 1
:3
5:
20
 P
M
 Cognitive Function and PH Respiration
DOI: 10.1159/000439227
5
normalized their Stroop 2 test, 2 their Stroop 3 test and 3 
their 5PT with unchanged other cognitive testing ( fig. 2 ). 
The scores of the TMT A and Stroop 2 test improved 
( table 2 ). There was no change in CTO or QMTO after 3 
months of disease-targeted therapy despite the improved 
blood oxygenation ( table 2 ). NYHA class, 6MWD, arte-
rial and peripheral oxygen saturation, and partial pres-
sure of oxygen improved ( table  2 ). HRQoL domains 
showed improved scales in the CAMPHOR symptom 
score and in the MLHFQ physical scale. Amongst pa-
rameters with significant changes, the calculated effect 
size (mean change divided by SD of the baseline) was 0.36 
for the CAMPHOR symptom scale, 0.35 and 0.16 for the 
TMT A and Stroop 2 test time, and 0.13 for the 6MWD 
test.
 Predictors of Cognitive Function, Exercise Capacity 
and HRQoL 
 Regression analysis with cognitive function at baseline 
and at FU as dependent factors showed that baseline CTO 
and the 6MWD test remained independent predictors in 
multivariate models ( table  3 ). The level of education, 
measured in years, correlated only with the baseline TMT 
B score (R = –0.512, p = 0.021) and the number of errors 
in the Stroop 3 test (R = –0.499, p = 0.025).
 The 6MWD correlated with age, NYHA class, HRQoL, 
cognitive function, CTO, QMTO, SaO 2 , SmvO 2 and the 
pulmonary vascular resistance ( table  4 ). Multivariate 
analysis revealed that baseline CTO was the only inde-
pendent predictor of 6MWD at baseline as well as at FU.
 The baseline HRQoL component correlated with the 
NYHA class, 6MWD, cognitive function component, the 
MMSE, CTO as well as SaO 2 and SmvO 2 mixed venous 
oxygen saturation ( table 5 ). The NYHA class and CTO at 
FU were both independent predictors of HRQoL.
 Discussion 
 Our data confirm that up to 45% of PH patients have 
cognitive deficits compared to reference populations, and 
we could show for the first time that aspects of cognitive 
function are improved after 3 months of disease-targeted 
 Table 3. Predictors of cognitive function
Univariate analysis  Multiple regression analysis
correlation
coefficient
p
value
co rrelation
coefficient
p
value
(Pearson) (R2)  
Age 0.457 0.043
NYHA class 0.490 0.028
HRQoL 0.517 0.02
6MWD –0.796 0.000 –0.476/–0.795 0.019/0.000
CTO –0.805 0.000 –0.805 0.000
SaO2 –0.681 0.001
Italicized figures represent the values for the cognitive function 
during FU as dependent variable.
 Table 4. Predictors of the 6MWD
Univariate analysis Multiple regression analysis
correlation
coefficient
(Pearson)
p
value
correlation
coefficient
p
value
  (R2)
Age –0.521 0.018
NYHA class –0.663 0.001
HRQoL –0.511 0.021
Cognitive function –0.796 0.000
CTO 0.752 0.000 0.718/0.727 0.000/0.000
QMTO 0.356 0.124
SaO2 0.605 0.005
SmvO2 0.740 0.000
PVR –0.510 0.022
Italicized figures represent the values for the 6MWD during FU 
as dependent variable. PVR = Pulmonary vascular resistance.
0
5
10
15
20
25
30
35
40
45
50
TMT Stroop 1 Stroop 2 Stroop 3 5PT
Baseline After 3 months
 Fig. 2. Percentages of PH patients with abnormal cognitive test re-
sults compared to standard populations are shown at baseline and 
after 3 month of disease-targeted therapies. 
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treatment. Cognitive function correlated with age, CTO 
and markers of disease severity, and CTO at baseline was 
the strongest predictor of cognitive function.
 Only one study has assessed cognitive function in PH 
so far and showed impaired cognitive function compared 
to controls in 57% of patients  [2] . The cognitive tests ap-
plied included the TMT and the Stroop tests, 2 out of 3 
tests used in our study. However, the authors did not eval-
uate correlations of PH disease markers with cognitive 
function, and there was no FU.
 In the present study, we used the TMT A and B, Stroop 
tests 1–3 and 5PT, widely accepted instruments for the 
evaluation of cognitive capacity  [19–22] . As the interpre-
tation of cognitive tests should be critically cautious, since 
they are influenced by education, age and other demo-
graphic factors, we compared our results with normative 
data stratified for age and educational level and thus min-
imized these confounding factors. We could show that up 
to 45% of PH patients had abnormal cognitive test results 
at baseline. Disease-targeted medical therapy was associ-
ated with the normalization of 3 of the 5 tests in 15, 10 and 
15% ( fig. 2 ). Furthermore, 2 of 5 cognitive scores (Stroop 
2 time and TMT A time, evaluating processing speed and 
executive functioning) improved. The effect size of cer-
tain measures of cognitive function even exceeded those 
of the 6MWD test. Interestingly, we had the chance to 
follow up a small control group (n = 4) consisting of 3 PH 
patients who were assessed at baseline and without ther-
apy and 1 patient who already had been prescribed PH-
targeted therapy at another hospital without change. 
These patients did not show improvements in cognitive 
testing or any other parameter after 3 months (data not 
shown), supporting our hypothesis that disease-targeted 
therapy may improve cognitive function in PH. However, 
a larger control group and randomized controlled trials 
would be necessary to corroborate this point.
 In a previous study, we found that patients with PH 
had lower CTO during exercise compared to controls and 
that acute vasodilation with nitric oxide increased CTO 
in PH patients but not in controls  [13] . Thus, we hypoth-
esized that long-term vasodilator therapy might similarly 
increase CTO in PH patients and, consequently, cogni-
tive function. However, we found that CTO did not im-
prove at FU despite an improved arterial oxygenation. 
The lack of a change in regional CTO despite an improve-
ment in clinical outcomes (6MWD, cognitive perfor-
mance) after 3 months of PH-targeted therapy might re-
late to an increase in cerebral oxygen consumption pro-
moted by an increased cerebral oxygen delivery 
associated with hemodynamic improvement. Moreover, 
improved hemodynamics might have enhanced CTO in 
brain regions other than those monitored with NIRS  [23–
25] . It has been postulated that the frontal lobe is an 
equivalent to executive function, which was tested by sev-
eral of our cognitive tests  [26] . However, it is likely that 
many other brain regions are involved  [27, 28] . Process-
ing speed, as assessed by the TMT, seems to be associated 
with the frontal and the parietal lobe  [29] . Additionally, 
patients after amygdalohippocampectomy have been 
found to have a decline in figural fluency, as measured in 
our study by the 5PT  [30] . Thus, it may well be that the 
prefrontal cortex measurements we performed do not 
sufficiently reflect the CTO of brain regions relevant for 
cognitive performance. Another potential explanation 
for an unchanged CTO despite the improvements in arte-
rial oxygenation might be an impaired cerebral autoregu-
lation. The increase in CTO in response to cognitive brain 
activation declines with physiological aging  [31] . This 
age-dependent decline may either be due to an altered 
functional brain organization or to an alteration of cou-
pling between brain cell activity and blood flow. In pa-
tients aged >65 years, cerebrovascular autoregulation was 
found to be less efficient compared to younger adults, re-
sulting in a decreased oxygen extraction during compro-
mised cerebral blood flow  [31, 32] . The mean age of our 
participants was 66 years and thus, the missing improve-
ment in CTO may have been caused by age-related defec-
tive autoregulation.
 We found that baseline CTO was the most powerful 
predictor of cognitive function and also predicted exer-
cise performance and HRQoL. Thus, despite an un-
changed CTO under therapy, CTO is independently cor-
related with cognitive function and markers of disease 
 Table 5. Predictors of HRQoL
Univariate analysis Multiple regression analysis
correlation 
coefficient
(Pearson)
p
value
correlation 
coefficient
(R2)
p
value
 
 
NYHA class 0.697 0.001 0.486/0.595 0.001/0.006
6MWD –0.511 0.021
Cognitive function 0.517 0.02
MMSE –0.587 0.006
CTO –0.519 0.019 –0.476 0.01
SmvO2 –0.530 0.016
SaO2 –0.208 0.379
Italicized figures represent the values for the HRQoL during 
FU as dependent variable.
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severity. CTO as tissue oxygenation measurement might 
be closely correlated with the SmvO 2 , a well-known mark-
er of disease severity. However, in our collective, CTO 
was clearly the best predictor of exercise capacity, HRQoL 
and cognitive function and performed much better than 
invasively or noninvasively measured arterial or mixed 
venous blood oxygenation or muscle tissue saturation. 
Thus, noninvasively measuring CTO using NIRS at base-
line may be a time- and cost-efficient technique to predict 
cognitive and exercise performance in PH.
 Several authors could show associations between cog-
nitive decline and HRQoL in pulmonary disease  [33, 34] . 
White et al.  [2] hypothesized that HRQoL and cognitive 
function were associated in PH patients; however, they 
failed to confirm this. One of their explanations was that 
they did not use a PH-specific questionnaire for HRQoL. 
In our study, we used PH-specific and well-evaluated 
questionnaires and could show that the component for 
cognitive function and HRQoL had a positive correlation 
( table  3 ). However, multivariate analysis revealed that 
only functional class assessment and CTO were indepen-
dent predictors of HRQoL. This might be partly explained 
by an intercorrelation between HRQoL symptom scales 
and NYHA functional class (R 2 = 0.697 for baseline and 
0.600 for FU). This is in line with other studies that found 
an association of low NYHA class with better HRQoL and 
high NYHA class with worse HRQoL in PH patients  [35, 
36] . In line with others, we could confirm a correlation 
between HRQoL and exercise performance  [4–6] .
 As in many previous studies, we confirmed that the 
6MWD test improves with PH-targeted treatment  [37–
39] . We found a good correlation between CTO and the 
6MWD test, but not with QMTO  [13] . We previously 
showed that CTO at maximal exercise was predictive of the 
maximal workload achieved, but QMTO was not. This 
points towards a role of the CTO decline and thus the brain 
in exercise limitation in PH patients. Our work reinforces 
several studies that postulate that CTO is a limiting factor 
for maximal exercise performance in a healthy population 
and in cardiorespiratory disease patients  [12–15] .
 The main limitations of this study are the small patient 
collective and a relatively short time of observation. How-
ever, PH is a rare disease and thus, the number of incident 
patients consenting to clinical trials is limited. As we fo-
cused on incident PH patients who were treated after di-
agnosis, we have no formal control group for this study. 
We did not include a prevalent control group on stable 
therapy. Although we used different cognitive tests in or-
der to have a comprehensive insight into cognitive func-
tion, every single cognitive test has its limitation and re-
flects only a specific part of the complex human cognitive 
system. Furthermore, repeated measurements may be in-
fluenced by learning effects. To reduce practice effects, we 
let the patients practice all tests before testing. The un-
changed cognitive performance in 4 patients who had no 
PH-targeted therapies might indicate that cognitive func-
tion improves in response to PAH-targeted therapy.
 In summary, PH is associated with cognitive impair-
ment, and disease-targeted therapy may improve cogni-
tive function. CTO was the strongest predictor of cogni-
tive performance, but also exercise capacity and HRQoL.
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